中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

101 records (took 0.028 seconds)

    NOVEL SIMIAN T-CELL LYMPHOTROPIC VIRUS
    23.
    发明申请
    NOVEL SIMIAN T-CELL LYMPHOTROPIC VIRUS 审中-公开
    新颖的SIMIAN T细胞淋巴瘤病毒

    公开(公告)号：US20140186383A1

    公开(公告)日：2014-07-03

    申请号：US14013947

    申请日：2013-08-29

    Applicant: Johns Hopkins University ,  The Government of the U.S.A. as Represented by the Secretary of the Department of He

    Inventor： William M. Switzer ,  Walid Heneine ,  Thomas M. Folks ,  Nathan D. Wolfe ,  Donald S. Burke ,  David M. Sintasath

    IPC: C07K14/005 ,  G01N33/569 ,  C07K16/10

    CPC classification number: C07K14/005 ,  C07K16/1036 ,  C12N7/00 ,  C12N15/86 ,  C12N2740/14021 ,  C12N2740/14022 ,  C12N2740/14043 ,  G01N33/56983

    Abstract: Disclosed are the simian T-cell lymphotropic virus type 3 subtype D (STLV-3 subtype D), isolated nucleic acid molecules encoding STLV-3 subtype D polypeptides, such as STLV-3 subtype D envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting STLV-3 subtype D, for example by detecting a STLV-3 subtype D nucleic acid or polypeptide in the sample. Accordingly, probes, primers, and antibodies for use in detecting STLV-3 subtype D nucleic acids or polypeptides are disclosed. Therapeutic compositions which include isolated nucleic acid molecules encoding a STLV-3 subtype D polypeptides or isolated polypeptides encoded by such nucleic acid molecules are also disclosed.

    Abstract translation: 公开了3型亚型T型细胞淋巴细胞病毒（STLV-3亚型D），编码STLV-3亚型D多肽的分离的核酸分子，例如STLV-3亚型D包膜，蛋白酶，聚合酶，tax，rex， 和衣壳多肽，由这种核酸编码的分离的多肽。 还公开了用于检测STLV-3亚型D的方法，例如通过检测样品中的STLV-3亚型D核酸或多肽。 因此，公开了用于检测STLV-3亚型D核酸或多肽的探针，引物和抗体。 还公开了包含编码STLV-3亚型D多肽的分离的核酸分子或由这种核酸分子编码的分离的多肽的治疗组合物。

    Peptide Domain Required For Interaction Between The Envelope of a Virus Pertaining to The Herv-W Interference Group and an Hasct Receptor
    27.
    发明申请
    Peptide Domain Required For Interaction Between The Envelope of a Virus Pertaining to The Herv-W Interference Group and an Hasct Receptor 审中-公开
    与Herv-W干扰组和Hasct受体有关的病毒信封之间相互作用所需的肽域

    公开(公告)号：US20090148454A1

    公开(公告)日：2009-06-11

    申请号：US12087893

    申请日：2007-02-09

    Applicant: Francois Mallet ,  Guy Oriol ,  Valerie Cheynet

    Inventor： Francois Mallet ,  Guy Oriol ,  Valerie Cheynet

    IPC: A61K39/395 ,  C07K14/00 ,  C12N15/11 ,  C12N15/00 ,  C12N5/08 ,  A61K31/7088 ,  A61K38/16 ,  C12Q1/70 ,  C07K16/18 ,  C12P21/00

    CPC classification number: C07K14/005 ,  A61K38/162 ,  A61K39/12 ,  A61K39/21 ,  C07K16/1036 ,  C07K2317/34 ,  C12N7/00 ,  C12N2740/10022 ,  C12N2740/10034 ,  C12N2740/10063 ,  G01N2333/15

    Abstract: The invention relates to a peptide domain required for interaction between the envelope of a virus pertaining to the HERV-W interference group and a hASCT receptor, comprising an N end point and a C end point. Said peptide domain is defined, at the N end point thereof, by a pattern formed by the amino acids L (Z)-proline-cysteine-X-cysteine in which Z is any amino acid, is a whole number between 2 and 30, and X is any amino acid, and at the C end point thereof, by a pattern formed by the amino acids serine-aspartic acid-Xa-Xb-Xc-Xd-Xe-aspartic acid-Xf-Xg-(Z) in which Xa, Xb, Xc, Xd, Xe, Xf, Xg are any amino acids, Z is any amino acid, B is a whole number between 15 and 25, preferably 20. The peptide domain comprises, between the N end point and the C end point, at least one pattern selected from the following patterns: a pattern formed by the amino acids cysteine-X2-X3-X4-X5-X6-cysteine in which X2, X3, X4, X5, X6 are any amino acids, and a pattern formed by the amino acids cysteine-X7-X8-X9-X10-X11-X12-X13-X14-X15-cysteine-trytophane in which X7, X8, X9, X10, X11, X12, X13, X14, X15 are any amino acids.

    Abstract translation: 本发明涉及涉及HERV-W干扰组的病毒包膜与hASCT受体之间的相互作用所需的肽结构域，其包含N个终点和C个终点。 所述肽结构域在N末端被由氨基酸L（Z） - 脯氨酸 - 半胱氨酸-X-半胱氨酸形成的图案定义，其中Z是任何氨基酸，其整数为2〜30， X为任何氨基酸，C端为氨基酸丝氨酸 - 天冬氨酸-Xa-Xb-Xc-Xd-Xe-天冬氨酸-Xf-Xg-（Z）形成的图案，其中 Xa，Xb，Xc，Xd，Xe，Xf，Xg是任何氨基酸，Z是任何氨基酸，B是15和25之间的整数，优选为20.肽结构域包括N端和C 从以下图案中选择的至少一种图案：由X2，X3，X4，X5，X6是任何氨基酸的氨基酸半胱氨酸-X 2 -X 3 -X 4 -X 5 -X 6半胱氨酸形成的图案，以及 其中X7，X8，X9，X10，X11，X12，X13，X14，X15的氨基酸半胱氨酸-X7-X8-X9-X10-X11-X12-X13-X14-X15-半胱氨酸 - 替硝唑形成的图案是 任何氨基酸。

    Intracellular antibodies for a retrovirus protein
    28.
    发明申请
    Intracellular antibodies for a retrovirus protein 审中-公开
    逆转录病毒蛋白的细胞内抗体

    公开(公告)号：US20050108780A1

    公开(公告)日：2005-05-19

    申请号：US10894194

    申请日：2004-07-19

    Applicant: Dubravka Drabek ,  Sylvia Dekker ,  Franklin Grosveld

    Inventor： Dubravka Drabek ,  Sylvia Dekker ,  Franklin Grosveld

    IPC: C07K16/10 ,  C07K16/40 ,  A01K67/027 ,  C12P21/00

    CPC classification number: C07K16/40 ,  A01K2217/05 ,  A01K2267/01 ,  C07K16/1036 ,  C07K2317/22 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/80

    Abstract: A transgenic organism is provided comprising a polynucleotide construct encoding an intracellular antibody which disrupts the catalysis of the production of the xenoantigen galactose α 1,3 galactose and/or a polynucleotide construct which encodes an intracellular antibody which binds specifically to a retrovirus protein, such as a PERV particle protein. Also described are methods for the production of such organisms. Cells, tissues and organs of the transgenic organism may be used in xenotransplantation.

    Abstract translation: 提供了一种转基因生物体，其包含编码细胞内抗体的多核苷酸构建体，该多核苷酸构建体破坏了异种人抗原半乳糖α1,3半乳糖的产生的催化和/或编码与抗逆转录病毒蛋白特异性结合的细胞内抗体的多核苷酸构建体，例如 PERV颗粒蛋白。 还描述了生产这种生物体的方法。 转基因生物的细胞，组织和器官可用于异种移植。

    Mutant Rev transdominant repressors of HIV replication
    29.
    发明授权
    Mutant Rev transdominant repressors of HIV replication 失效
    突变型转录反义寡核苷酸HIV复制

    公开(公告)号：US6162898A

    公开(公告)日：2000-12-19

    申请号：US138069

    申请日：1998-08-21

    Applicant: Bryan R. Cullen

    Inventor： Bryan R. Cullen

    IPC: A61K38/00 ,  C07K14/15 ,  C07K14/16 ,  C07K16/10 ,  C12N15/49 ,  G03C7/30 ,  G03C7/36 ,  C07K14/00

    CPC classification number: C07K14/005 ,  A61K38/00 ,  C07K16/1036 ,  C12N2740/10022 ,  C12N2740/10043 ,  C12N2740/14022 ,  C12N2740/14043 ,  C12N2740/16322 ,  G03C7/3013 ,  G03C7/36

    Abstract: Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. And in some cases both the Rev and the Rex function and are, active in more than one viral species. Such transdominant viral mutants are useful as anti-viral agents to, for example of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g. HIV-1, infection.

    Abstract translation: 衍生自HIV-1的rev基因产物或HTLV-1的rex基因产物和相应的突变基因的具有抑制HIV-1中Rev功能和/或Rex功能的能力的病毒基因表型表达的显性阻遏物 HTLV-I和HTLV-II。 在某些情况下，Rev和Rex的功能都是活跃在一种以上的病毒物种中。 这样的显性病毒突变体可用作抗病毒剂，例如这些跨主导抑制剂可用于诸如细胞内免疫的治疗方法中，以保护细胞免受病毒的有害影响，例如， HIV-1，感染。

Patent Agency Ranking